Optimizing the dosing regimens for intravascular administrations of oncolytic adenovirus

被引：0

作者：

Tsai, V ^{[1
]}

Johnson, DE ^{[1
]}

Schluep, T ^{[1
]}

Quijano, E ^{[1
]}

Wen, SF ^{[1
]}

Ralston, R ^{[1
]}

Demers, GW ^{[1
]}

Ramachandra, M ^{[1
]}

机构：

[1] Canji Inc, San Diego, CA USA

来源：

IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY | 2004年

关键词：

D O I：

暂无

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The objective of this study was to determine the impact of multiple-dose regimens on the activity of the final dose of an oncolytic adenovirus. Groups of tumor-bearing mice were dosed with the oncolytic adenovirus 01/PEME on each of 1, 2, 3, or 4 consecutive days prior to final treatment with a single dose of a different oncolytic adenovirus carrying the reporter gene, dl01/07-luc. Delivery and replication of the dl01/07-luc in the tumor and liver were determined by quantifying virus DNA copies by PCR and reporter gene activity by a luciferase enzymatic assay. Our results showed that there was a regimen-dependent effect after multiple prior intravenous administrations on the biological activity of dl01/07-luc.

引用

页码：429 / 436

页数：8

共 50 条

[11] Enadenotucirev (ColoAd1) a replication competent oncolytic adenovirus: Construction of a cloning platform for optimizing oncolytic virus activity and transgene delivery
Kodialbail, P.
Rasiah, N.
Calderon, H.
Beadle, J.
Seymour, L.
Champion, B. R.
Fisher, K.
Brown, A. C. N.
HUMAN GENE THERAPY, 2014, 25 (12) : A25 - A25
[12] Adenovirus as a Vector and Oncolytic Virus
Matsunaga, Wataru
Gotoh, Akinobu
CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (06) : 4826 - 4840
[13] A multitasking oncolytic adenovirus vector
Toth, K
Doronin, K
Tollefson, AE
Wold, WSM
MOLECULAR THERAPY, 2003, 7 (04) : 435 - 437
[14] Optimization of dosing regimens and dosing in special populations
Sime, F. B.
Roberts, M. S.
Roberts, J. A.
CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (10) : 886 - 893
[15] Development of the triple-mutant oncolytic adenovirus for treatment of metastatic cancer by means of intravascular virus administration.
Shayakhmetov, Dmitry
Di Paolo, Nelson Cesar
Wyche, Henry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[16] Development of an Oncolytic Adenovirus for Systemic Intravascular Administration for Treatment of Solid and Disseminated Tumors in Mouse Lung Adenocarcinoma Model
Atasheva, Svetlana
Emerson, Corey
Young, Cedrick
Stewart, Phoebe
Shayakhmetov, Dmitry
MOLECULAR THERAPY, 2019, 27 (04) : 123 - 124
[17] Optimizing fosfomycin dosing regimens in critically ill patients with and without continuous renal replacement therapy
Charoensareerat, Taniya
Bunrit, Phongphak
Phanpoka, Sasina
Netthanomsak, Thananya
Rungkitwattanakul, Dhakrit
Pattharachayakul, Sutthiporn
Srisawat, Nattachai
Chaijamorn, Weerachai
JOURNAL OF CRITICAL CARE, 2025, 85
[18] Optimizing Amoxicillin/Clavulanic Acid Dosing Regimens in Patients on Maintenance High-Flux Hemodialysis
De Schuyter, Kelly
Colin, Pieter J.
Vanommeslaeghe, Floris
Delanghe, Sigurd
De Cock, Pieter
Veys, Nic
De Paepe, Peter
Van Biesen, Wim
Eloot, Sunny
AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (01) : 153 - 156
[19] Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF
Zhang, Song-Nan
Choi, Il-Kyu
Huang, Jing-Hua
Yoo, Ji-Young
Choi, Kyung-Ju
Yun, Chae-Ok
MOLECULAR THERAPY, 2011, 19 (08) : 1558 - 1568
[20] Strategies for optimizing hemoglobin response in cancer patients: focus on new epoetin alfa dosing regimens
Sabbatini, P
EJC SUPPLEMENTS, 2004, 2 (02): : 36 - 40

← 1 2 3 4 5 →